Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-Current Debt (2016 - 2025)

Cytosorbents' Non-Current Debt history spans 9 years, with the latest figure at $16.7 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $16.7 million for Q4 2025, up 19.08% from a year ago — trailing twelve months through Dec 2025 was $16.7 million (up 19.08% YoY), and the annual figure for FY2025 was $16.7 million, up 19.08%.
  • Non-Current Debt for Q4 2025 was $16.7 million at Cytosorbents, up from $14.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $16.7 million in Q4 2025 to a low of $1.9 million in Q1 2024.
  • The 4-year median for Non-Current Debt is $13.7 million (2024), against an average of $10.0 million.
  • The sharpest move saw Non-Current Debt plummeted 49.14% in 2023, then surged 635.61% in 2025.
  • Year by year, Non-Current Debt stood at $5.0 million in 2022, then plummeted by 49.14% to $2.5 million in 2023, then surged by 450.4% to $14.0 million in 2024, then increased by 19.08% to $16.7 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $16.7 million, $14.6 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.